| 53 | 0 | 38 |
| 下载次数 | 被引频次 | 阅读次数 |
乳腺癌是死亡率较高的恶性肿瘤之一，其中激素受体阳性和人表皮生长因子受体2阴性亚型较为常见。内分泌治疗在该亚型乳腺癌治疗中占据重要地位。大量研究证实，联合细胞周期蛋白依赖性激酶4和6抑制剂能明显提升疗效。相较于国内已上市的其他细胞周期蛋白依赖性激酶4和6抑制剂，瑞波西利在临床应用中具有独特优势，其在激素受体阳性和人表皮生长因子受体2阴性晚期乳腺癌的一线治疗中展现出显著的总生存期获益，不仅适用于内脏危象患者，还可特异性抑制代偿性细胞周期蛋白依赖性激酶6-cyclin D3二聚体，防止肿瘤细胞通过旁路激活产生耐药，实现长久的临床获益。现通过综述国内已上市的细胞周期蛋白依赖性激酶4和6抑制剂药物治疗的研究进展，探讨瑞波西利在激素受体阳性和人表皮生长因子受体2阴性乳腺癌中的临床应用，以期为优化我国乳腺癌患者的治疗方案和提升疗效提供参考依据。
Abstract：Breast cancer is one of the malignant tumors with relatively high mortality rates, with the hormone receptor(HR) positive and human epidermal growth factor receptor 2(HER2) negative subtype being prevalent. Endocrine therapy plays an important role in the treatment system of HR+/HER2-breast cancer. Many studies have shown that the combination with cyclin-dependent kinases 4/6(CDK4/6) inhibitors can significantly improve efficacy. Compared with other CDK4/6 inhibitors marketed in China, ribociclib has unique clinical manifestations. In the first-line treatment of HR+/HER2-advanced breast cancer, it demonstrates a significant benefit in prolonging overall survival(OS). It not only applies to patients with visceral crisis, but also effectively inhibits the compensatory CDK4/6-cyclin D3 dimer, preventing tumor cells from developing drug resistance through bypass activation and achieving long-term clinical benefits. By reviewing the research progress of CDK4/6 inhibitor therapy marketed in China, and conducting an in-depth discussion on the clinical application progress of ribociclib in HR+/HER2-breast cancer, we aimed to provide a reference for optimizing treatment regimens and improving therapeutic effects for breast cancer patients in China.
[1]BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2024, 74(3):229.
[2]CORTET M, BERTAUT A, MOLINIÉF, et al. Trends in molecular subtypes of breast cancer:description of incidence rates between2007 and 2012 from three French registries[J]. BMC Cancer,2018, 18(1):161.
[3]HOWLADER N, CRONIN K A, KURIAN A W, et al. Differences in breast cancer survival by molecular subtypes in the United States[J]. Cancer Epidemiol Biomarkers Prev, 2018, 27(6):619.
[4]GRADISHAR W J, MORAN M S, ABRAHAM J, et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2024, 22(5):331.
[5]HANKER A B, SUDHAN D R, ARTEAGA C L. Overcoming endocrine resistance in breast cancer[J]. Cancer Cell, 2020,37(4):496.
[6]李艳,崔英杰,刘娟娟,等.用于乳腺癌的细胞周期蛋白依赖性激酶4/6选择性抑制剂瑞波西利[J].中国新药杂志, 2025, 34(4):364.
[7]CARDOSO F, PALUCH-SHIMON S, SENKUS E, et al. 5th ESOESMO international consensus guidelines for advanced breast cancer(ABC 5)[J]. Ann Oncol, 2020, 31(12):1623.
[8]梁敏渟,杨辞秋,王坤. CDK4/6抑制剂在乳腺癌治疗中的研究进展[J].循证医学, 2023, 23(2):65.
[9]BRAAL C L, JONGBLOED E M, WILTING S M, et al. Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib:similarities and differences[J]. Drugs, 2021, 81(3):317.
[10]DING L, CAO J Q, LIN W, et al. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer[J]. Int J Mol Sci, 2020, 21(6):1960.
[11]JI Y, SCHILLER H, YANG S, et al. Use of pharmacokinetic and pharmacodynamic data to develop the CDK4/6 inhibitor ribociclib for patients with advanced breast cancer[J]. Clin Pharmacokinet,2024, 63(2):155.
[12]SANÒM V, MARTORANA F, LAVENIA G, et al. Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials[J]. Expert Rev Anticancer Ther, 2022, 22(4):343.
[13]SLAMON D J, DIÉRAS V, RUGO H S, et al. Overall survival with palbociclib plus letrozole in advanced breast cancer[J]. J Clin Oncol, 2024, 42(9):994.
[14]CRISTOFANILLI M, RUGO H S, IM S A, et al. Overall survival with palbociclib and fulvestrant in women with HR+/HER2-ABC:updated exploratory analyses of PALOMA-3, a double-blind, phaseⅢrandomized study[J]. Clin Cancer Res, 2022, 28(16):3433.
[15]XU B H, HU X C, LI W, et al. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer:primary results from PALOMA-4[J]. Eur J Cancer, 2022, 175:236.
[16]SLEDGE G W Jr, TOI M, NEVEN P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2:a randomized clinical trial[J].JAMA Oncol, 2020, 6(1):116.
[17]GOETZ M P, TOI M, HUOBER J, et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+,HER2-advanced breast cancer:final overall survival results of MONARCH 3[J]. Ann Oncol, 2024, 35(8):718.
[18]RASTOGI P, O’SHAUGHNESSY J, MARTIN M, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive,human epidermal growth factor receptor 2-negative, high-risk early breast cancer:results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes[J]. J Clin Oncol, 2024, 42(9):987.
[19]秦莉莉,张少华,宋华,等.达尔西利在乳腺癌治疗中的研究进展[J].临床肿瘤学杂志, 2024, 29(1):90.
[20]XU B H, ZHANG Q Y, ZHANG P, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer:a randomized, phase 3 trial[J]. Nat Med, 2021, 27(11):1904.
[21]ZHANG P, ZHANG Q Y, TONG Z S, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive,HER2-negative advanced breast cancer(DAWNA-2):a multicentre,randomised, double-blind, placebo-controlled, phase 3 trial[J].Lancet Oncol, 2023, 24(6):646.
[22]DANIEL D, KUCHAVA V, BONDARENKO I, et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer:a multicentre,randomised, double-blind, placebo-controlled phaseⅡtrial[J].Int J Cancer, 2021, 148(10):2557.
[23]TAN A R, WRIGHT G S, THUMMALA A R, et al. Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer:final efficacy and subgroup analysis from a randomized phaseⅡstudy[J]. Clin Cancer Res, 2022, 28(4):629.
[24]PRAT A, SAURA C, PASCUAL T, et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer(CORALLEEN):an open-label, multicentre, randomised, phase 2trial[J]. Lancet Oncol, 2020, 21(1):33.
[25]VILLACAMPA G, FALATO C, PARÉL, et al. Pre-operative ribociclib plus letrozole versus chemotherapy:health-related quality of life outcomes from the SOLTI CORALLEEN trial[J].Eur J Cancer, 2022, 174:232.
[26]No Authers. Corrigendum to Rationale and trial design of NATALEE:a PhaseⅢtrial of adjuvant ribociclib+endocrine therapy versus endocrine therapy alone in patients with HR+/HER2-early breast cancer[J]. Ther Adv Med Oncol, 2023, 15:17588359231201818.
[27]SLAMON D, LIPATOV O, NOWECKI Z, et al. Ribociclib plus endocrine therapy in early breast cancer[J]. N Engl J Med,2024, 390(12):1080.
[28]PARATI M C, PEDERSINI R, PEREGO G, et al. Ribociclib in the treatment of hormone-receptor positive/HER2-negative advanced and early breast cancer:overview of clinical data and patients selection[J]. Breast Cancer, 2022, 14:101.
[29]HORTOBAGYI G N, STEMMER S M, BURRIS H A, et al.Updated results from MONALEESA-2, a phaseⅢtrial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer[J].Ann Oncol, 2018, 29(7):1541.
[30]SLAMON D J, NEVEN P, CHIA S, et al. PhaseⅢrandomized study of ribociclib and fulvestrant in hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer:MONALEESA-3[J]. J Clin Oncol, 2018, 36(24):2465.
[31]LU Y S, IM S A, COLLEONI M, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre-and perimenopausal patients with HR+/HER2-advanced breast cancer in MONALEESA-7:a phaseⅢrandomized clinical trial[J]. Clin Cancer Res, 2022, 28(5):851.
[32]SLAMON D J, NEVEN P, CHIA S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phaseⅢrandomized MONALEESA-3 trial:updated overall survival[J]. Ann Oncol, 2021, 32(8):1015.
[33]NEVEN P, FASCHING P A, CHIA S, et al. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2-advanced breast cancer receiving first-line ribociclib plus fulvestrant[J]. Breast Cancer Res, 2023, 25(1):103.
[34]HARBECK N, FRANKE F, VILLANUEVA-VAZQUEZ R, et al.Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy:results from a phaseⅢrandomized clinical trial(MONALEESA-7)[J]. Ther Adv Med Oncol, 2020, 12:1758835920943065.
[35]LU Y S, BIN MOHD MAHIDIN E I, AZIM H, et al. Final results of RIGHT choice:ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer[J]. J Clin Oncol, 2024, 42(23):2812.
[36]徐菲,李培勇.瑞波西利联合内分泌治疗用于绝经前侵袭性HR+/HER2-晚期乳腺癌患者:随机Ⅱ期RIGHT Choice试验[J].循证医学, 2023, 23(2):92.
[37]LU Y S, BIN MOHD MAHIDIN E I, AZIM H, et al. Abstract GS1-10:primary results from the randomized phaseⅡRIGHT choice trial of premenopausal patients with aggressive HR+/HER2–advanced breast cancer treated with ribociclib+endocrine therapy vs physician's choice combination chemotherapy[J]. Cancer Res, 2023, 83(S5):GS1.
[38]PROVENZANO L, DIECI M V, CURIGLIANO G, et al. Realworld effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients:results from the multicenter PALMARES-2 study[J]. Ann Oncol, 2025, 36(7):762.
[39]PANTANO F, SCAFETTA R, CURIGLIANO G, et al. 394P CDK4/6 inhibitors in metastatic breast cancer:an Italian real-world experience[J]. Ann Oncol, 2023, 34:S346.
[40]杨梅,黄帅,舒茂. MONALEESA-7研究:瑞波西利联合内分泌治疗激素受体阳性绝经前晚期乳腺癌的疗效分析[J].循证医学,2023, 23(2):78.
[41]TRIPATHY D, HORTOBAGYI G N, CHAN A, et al. Pooled safety analysis of first-line ribociclib(RIB)plus endocrine therapy(ET)in HR+/HER2–advanced breast cancer(ABC)[J]. Ann Oncol,2019, 30:iii53.
基本信息:
DOI：10.19577/j.1007-4406.2026.03.019
中图分类号:R737.9
引用信息:
[1]胡紫威,王春建,唐海.瑞波西利在激素受体阳性和人表皮生长因子受体2阴性乳腺癌治疗中的研究进展[J].中国临床药学杂志,2026,35(03):283-288.DOI:10.19577/j.1007-4406.2026.03.019.
2026-03-25
2026-03-25